CHAPTER 1 RUSSIA IVF MARKET
1.1. EUROPE IVF MARKET (REVENUE AND NUMBER OF CYCLES)
1.2. RUSSIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
1.2.1. Market size and forecast
1.2.2. Russia IVF market, by end user
1.2.2.1. Market size and forecast
1.2.2.2. Fertility clinics
1.2.2.3. Hospitals
1.2.2.4. Surgical centers
1.2.2.5. Clinical research institutes
1.2.3. Russia IVF market, by cycle type
1.2.3.1. Market size and forecast
1.2.3.2. Fresh IVF cycles (non-donor)
1.2.3.3. Thawed IVF cycles (non-donor)
1.2.3.4. Donor egg IVF cycles
1.2.4. Russia IVF market, by type
1.2.4.1. Market size and forecast
1.2.4.2. Non-ICSI IVF cycles
1.2.4.3. ICSI-assisted IVF cycles
1.2.5. Russia IVF market by pharmacological modality
1.2.5.1. Overview
1.2.5.2. Key trends
1.2.5.3. Market size and forecast
1.2.5.4. Duration of therapy
1.2.5.5. Segmentation of drugs for IVF
1.2.5.5.1. Clomiphene citrate
1.2.5.5.2. Aromatase inhibitors
1.2.5.5.3. Gonadotropins & gonadotropin-releasing hormone (GnRH)
1.2.5.5.4. Follicle-stimulating hormone (FSH)
1.2.5.5.5. Progesterone
1.2.5.5.6. Others
1.2.5.6. Mode of administration
1.2.5.6.1. Oral
1.2.5.6.2. Injectable
1.2.5.6.3. Vaginal
1.2.6. Market dynamics
1.2.6.1. Drivers
1.2.6.1.1. Rise in popularity of fertility tourism
1.2.6.1.2. Advanced IVF facilities and treatment options
1.2.6.2. Restraint
1.2.6.2.1. Inadequate reimbursement policies
1.2.7. Regulatory issues, legislations, and authorities
1.2.8. Insurance reimbursement scenario
CHAPTER 2 COMPANY PROFILES
2.1. AVA-PETER CLINIC
2.1.1. Company overview
2.1.2. Company snapshot
2.1.3. Product portfolio
2.2. MD MEDICAL GROUP INVESTMENTS PLC (MD MEDICAL GROUP)
2.2.1. Company overview
2.2.2. Company snapshot
2.2.3. Operating business segments
2.2.4. Product portfolio
2.2.5. Business performance
2.2.6. Key strategic moves and developments
2.3. IVF RUSSIA (THE INTERNATIONAL CENTRE OF THE REPRODUCTIVE MEDICINES)
2.3.1. Company overview
2.3.2. Company snapshot
2.3.3. Operating business segments